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Retinoid receptors (RARs) upon a proper ligand binding
act as all-trans retinoic acid-inducible transcription fac-
tors interacting as heterodimers with retinoid X receptors
(rexinoid receptors, RXRs).
The objective of this study was to evaluate all retinoid/
rexinoid nuclear receptor subtypes (RARalpha, RARbeta,
RARgamma, RXRalpha, RXRbeta, RXRgamma) expression
pattern in thyroid tumour tissue of patients with different
types of thyroid cancer in order to compare it with that of
the intact thyroid tissue of the corresponding patient. The
expression of the retinoid/rexinoid nuclear receptor sub-
types has been analyzed by the semiquantitative RT-PCR
technique.
Papillary thyroid carcinoma (PTC) patients expressed
RXRgamma when compared to non-neoplastic thyroid tis-
sues of the corresponding patients that were lacking to
express RXRgamma or its expression was very low. More-
over, we have found significantly increased expression of
RARalpha and RARgamma in overall group of PTC
patients. This increase was detected in cases with positive
lymph node metastasis (LNM), but not with negative
LNM. On the other hand, RARbeta was significantly
reduced in the subgroup of classic variant (CV) of papil-
lary carcinoma.
Expression of RXRgamma in the patient with anaplastic
carcinoma was found to be lower than that of patients
with papillary carcinoma. Follicular adenoma or malignant
lymphoma, and also nonmalignant follicular nodules were
expressing all RAR and RXR subtypes. On the other hand,
hyperplastic nodule was found to express all RAR or RXR
subtypes, except RARgamma.
In conclusion, the data on the differences in RAR and
RXR subtype mRNA expression patterns in various thyr-
oid carcinomas might thus enhance therapeutical potenti-
alities, and thus they may find exploitation in clinical
oncology, predominantly, in the differential diagnostics of
human thyroid neoplasms.
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